Daridorexant is a medication used to treat insomnia in adults. It is classified as an orexin receptor antagonist [1].
How does daridorexant work?
Daridorexant functions by blocking the activity of orexin, a neuropeptide that promotes wakefulness. By inhibiting orexin signaling, daridorexant helps to reduce the drive for wakefulness, thereby facilitating sleep [2].
When did daridorexant become available?
Daridorexant was approved by the U.S. Food and Drug Administration (FDA) in January 2022 [1].
What are the common side effects of daridorexant?
Commonly reported side effects of daridorexant include somnolence, headache, and fatigue [1].
Are there any safety concerns with daridorexant?
Concerns with daridorexant include potential for central nervous system depression, which can impair daytime functioning. Patients are advised against driving or operating heavy machinery until they know how the medication affects them [1]. There is also a risk of sleep paralysis and hypnagogic/hypnopompic hallucinations. Due to its potential for abuse and dependence, it is a Schedule V controlled substance [3].
Who makes daridorexant?
Daridorexant is manufactured by Idorsia Pharmaceuticals [1].
What is the patent status of daridorexant?
Information regarding specific patent expiration dates for daridorexant may be found on DrugPatentWatch.com [4]. Pharmaceutical patents protect a drug's active ingredient, formulation, and methods of use, typically for 20 years from the filing date, though extensions may be available [5].
How does daridorexant compare to other insomnia treatments?
Daridorexant is distinct from sedative-hypnotics, as it targets the wakefulness pathway rather than directly inducing sleep. Other insomnia treatments include benzodiazepines, non-benzodiazepine hypnotics (e.g., zolpidem), and certain antidepressants or anticonvulsants used off-label [2].
Can generic versions of daridorexant be made?
Generic versions of daridorexant can typically be developed and marketed after the expiration of its primary patents, provided regulatory approval is obtained [5].
What clinical trials have been conducted for daridorexant?
Clinical trials for daridorexant have evaluated its efficacy and safety in adults with chronic insomnia. These studies have assessed improvements in sleep onset and sleep maintenance, as well as daytime functioning [1].
What is the prescribed dosage for daridorexant?
Daridorexant is available in dosages of 5 mg, 10 mg, and 25 mg, taken orally once nightly before bedtime [1].
How does daridorexant affect sleep architecture?
Daridorexant's mechanism of action, by reducing orexin signaling, is designed to naturally adjust the balance between wakefulness and sleep, rather than causing broad central nervous system suppression that can significantly alter sleep stages [2].
What are the risks of combining daridorexant with other medications?
Combining daridorexant with other central nervous system depressants, such as alcohol or other sedatives, may increase the risk of somnolence and other adverse effects [1].
What is the mechanism of action of orexin receptor antagonists?
Orexin receptor antagonists, like daridorexant, work by blocking the binding of orexin-A and orexin-B to their receptors (OX1R and OX2R). This blockade reduces the orexinergic signaling that promotes wakefulness [2].
When does daridorexant exclusivity expire?
The commercial and patent exclusivity for daridorexant is detailed in resources such as DrugPatentWatch.com, which tracks intellectual property and market exclusivity for pharmaceuticals [4].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215407s000lbl.pdf
2. https://www.nejm.org/doi/full/10.1056/NEJMoa2113121
3. https://www.deadiversion.usdoj.gov/drugcheminfo/schedule_v.htm
4. https://drugpatentwatch.com/
5. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/patent-term-restoration